Company

Management Team

Brian O'Callaghan
President and Chief Executive Officer

David Renas, JD
Chief Financial Officer and General Counsel

Don Brown
Chief Operating Officer

Howard Levy, MD, PhD
Chief Scientific Officer

Andrew Gomperts, JD
Head of Corporate and Business Development

Clive Bertram
Head of European Commercialization

Kristine Figueroa
Vice President of Human Resources

Wayne Frost, Pharm.D, JD
Vice President of Regulatory Affairs and Quality Assurance

Brian O'Callaghan

President and Chief Executive Officer

Mr. O'Callaghan joined Sangart as President and Chief Executive Officer in June 2008. Mr. O'Callaghan brings a breadth of experience to Sangart, having held senior positions with a number of pharmaceutical and biotechnology companies in both Europe and the US. These include senior positions with Pfizer in the UK and Merck Serono in Germany, before becoming President and CEO of BioPartners, a Swiss based biotechnology company. Since relocating to the US, Mr. O'Callaghan has held senior management positions at Novartis, where he served as General Manager of their Transplantation, Immunology and Infectious Disease businesses, as well as at Covance, a clinical research firm, where he served as General Manager of their Cardiac safety and IVRS businesses. Mr. O'Callaghan joins Sangart from NPS Pharmaceuticals, where he served as Chief Commercial Officer. Mr. O'Callaghan brings his extensive general management background in the pharmaceutical, biotechnology and clinical research sectors, as well as his significant international experience, to lead Sangart through regulatory submission and commercial launch of MP4.

David Renas, JD

Chief Financial Officer and General Counsel

Mr. Renas has over twenty years of experience in financial and legal matters, including service as Sangart's Chief Financial Officer and General Counsel since January 2002. Prior to joining Sangart, Mr. Renas was engaged as an attorney in private practice with Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner and as a Certified Public Accountant with Deloitte Haskins & Sells (now Deloitte & Touche). He also served as an accounting instructor at San Diego State University and has authored several law articles. Mr. Renas holds a Bachelor of Arts degree in Economics from Stanford University and a Juris Doctorate from the University of California at Davis.

Don Brown

Chief Operating Officer

Mr. Brown joined Sangart in April, 2009 as Chief Operating Officer. Prior to Sangart, he served as President & COO of Zosano Pharma in Fremont, CA. While with Zosano he oversaw the highly successful conclusion of a Phase 2 clinical trial, raised an additional $30 million Series C financing round from existing venture capital investors, and led the business development activities to a successful partnering conclusion prior to leaving. Prior to Zosano, Mr. Brown served as Senior Executive Vice President at Aventis with global responsibility for manufacturing, engineering, quality assurance, supply chain, and purchasing operations. Mr. Brown was also a co-founder of Calvert Laboratories in 1998. Calvert is a Pharmacology/Toxicology firm providing preclinical and environmental services to a vast number of companies in North America. A chemist by education, Mr. Brown has enjoyed a career of continued growth in the pharmaceutical industry, and has spent much of his career in the international arena negotiating with foreign governments and building manufacturing plants in six (6) countries.

Howard Levy, MD, PhD

Chief Scientific Officer

Dr. Levy joined Sangart, Inc. in December 2008 as Chief Scientific Officer coordinating Pharmaceutical Research and Development, Preclinical Research and Development, and Clinical. He has designed and executed Phase I-IV studies of new pharmaceutical agents for Trauma, Hemophilia, Intracranial Hemorrhage, Severe Sepsis, Acute Respiratory Distress Syndrome (ARDS), Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Pancreatitis, Serious Infections, Burns and Deep Venous Thrombosis prevention studies for over 20 years. He is a Critical Care and Pulmonary physician and previously served as Chief of Critical Care Medicine at the University of New Mexico in Albuquerque, New Mexico for 11 years through 2000. Dr Levy was Associate Vice President at Novo Nordisk Inc based in Princeton, New Jersey from February 2006 and was responsible for Clinical Research of the Hemostasis platform, Trauma, Inflammation/Oncology, Growth Hormone and Hormone Therapy for menopause therapeutic areas, leading teams researching initial and additional indications for recombinant human activated Factor VII and derivatives (for Hemophilia and Trauma), and Factors VII, IX and XIII, Growth Hormone, systemic and topical Estrogens, anti-Interferon, anti-Interleukins and other biologic compounds. In October 2000 he was employed by Eli Lilly and company as Medical Director Acute Care in the United States Medical Division of with responsibility for the Xigris (Activated Protein C), ReoPro and prasugrel teams, in the therapeutic areas of Severe Sepsis and Cardiovascular Disease. Dr Levy was awarded a B Sc in Anatomy and Physiology at the University of Witwatersrand, Johannesburg, South Africa in 1975 and MB BCh in 1978. He completed a Pulmonary and Critical Care Fellowship at the City of Hope/Veterans Administration Long Beach/University of Irvine, CA in 1989. He obtained his PhD from the University of the Witwatersrand in 1996 and a Masters in Medical Management at Carnegie-Mellon in 2001.

Andrew Gomperts, JD

Head of Corporate and Business Development

Mr. Gomperts joined Sangart in September 2005. Prior to Sangart, he was a Director in the Venture Operations group at Idealab, a venture capital holding company. Mr. Gomperts was also previously in senior management with Prometheus Laboratories, a specialty pharmaceutical company, where he was responsible for mergers & acquisitions, corporate partnering, licensing and strategic planning. Prior to Prometheus, he spent five years with McKinsey & Company, where he advised the senior management of large and mid-sized companies on strategic, financial and operational matters. Mr. Gomperts received Bachelor of Science degrees in Chemistry and Economics from the University of California, Los Angeles, a JD from Stanford Law School and an MBA from the Wharton School.

Clive Bertram

Head of European Commercialization

Mr. Bertram joined Sangart in December 2008. He brings over 15 years of strategic marketing and sales experience in both international and local markets. Prior to Sangart he has held senior strategic marketing positions in a number of pharmaceutical and biopharmaceutical companies. These include Senior Director of International Marketing at Pharmion, European Marketing Director at Chiron Biopharmaceuticals, Global Commercial Development at Celltech, as well as several Sales & Marketing positions at Eli Lilly and company. He is an experienced leader across many functions and countries with a specific focus on development and implementation of strategic and operational plans from early disease strategy through development and launch to established brands.

Kristine Figueroa

Vice President of Human Resources

Ms. Figueroa joined Sangart in November, 2008. Ms. Figueroa brings more than 13 years of experience in human resources. Prior to joining Sangart, Ms. Figueroa held senior management positions at SGX Pharmaceuticals and Kintera overseeing the Human Resources function. Ms. Figueroa also held management positions as a HR business partner and compensation professional with Elan Pharmaceuticals. Ms. Figueroa holds a B.S. in Business Administration and a M.S. in Human Resources Management from Troy State University. Ms. Figueroa holds certifications as a Certified Compensation Professional (CCP) and Global Remuneration Professional (GRP) through World at Work.

Wayne Frost, Pharm.D, JD

Vice President of Regulatory Affairs and Quality Assurance

Dr. Wayne Frost joined Sangart in February 2009 as Vice President of Regulatory Affairs and Quality Assurance. Prior to joining Sangart he was Vice President, Regulatory Affairs and Quality Assurance at Metabasis Therapeutics and Prometheus Laboratories. He has also held positions at Amgen as Global Regulatory Leader for Aranesp, Pfizer Global Research and Development as Regulatory Therapeutic Area Head for the Respiratory, Allergy, Inflammation, Immunology and Oncology, Astra Pharmaceuticals as Head of Regulatory for Local Anesthetics and Critical Care Therapeutics, Bayer Pharmaceuticals for Ciprofloxacin antibiotic drug development and Key Pharmaceuticals on Sustained-Release drug delivery. Dr Frost is a guest lecturer at Yale University School of Medicine, Department of Pharmacoepidemiology and Public Health on Food and Drug Law. Dr. Frost earned his Pharm.D. at Creighton University School of Pharmacy completed a post-doctoral fellowship in pharmacokinetics/infectious diseases at SUNY-Buffalo and received his J. D. from the University of Connecticut School of Law.